Related Experiment Video
Updated: Jan 6, 2026
08:07
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
7.6K
Plasma proteins and osteosarcoma risk: causal evidence from Mendelian randomization
Hanjun Ma1,2, Ju Liao1, Zonglong He1
1Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, 533000, Guangxi, China.
Discover Oncology
|November 11, 2025
Summary
This study used Mendelian randomization to find blood protein biomarkers for osteosarcoma (OS) risk. Glyoxalase 1 (GLO1) showed a protective effect, suggesting its potential as an OS biomarker.
Area of Science:
- Oncology
- Genetics
- Proteomics
Background:
- Osteosarcoma (OS) is an aggressive bone cancer with limited early detection biomarkers.
- Identifying blood-based markers for OS risk and prognosis is a critical unmet need.
Purpose of the Study:
- To investigate causal relationships between circulating plasma proteins and osteosarcoma risk.
- To identify potential protein biomarkers for early detection and prognosis of OS.
Main Methods:
- Utilized Mendelian randomization (MR) analysis.
- Employed genome-wide association study (GWAS) summary statistics for 3,282 plasma protein traits.
- Leveraged data from the IEU Open GWAS Project and the FinnGen consortium.
Main Results:
- Identified 59 proteins positively associated with OS risk and 66 inversely associated.
- Lactoylglutathione lyase (Glyoxalase 1, GLO1) demonstrated a significant protective effect against OS risk (IVW OR = 0.2871, P = 2.7580×10⁻⁵).
- The protective association of GLO1 remained significant after false discovery rate (FDR) correction (FDR_pavl < 0.1).
Conclusions:
- Circulating proteins, particularly GLO1, show potential as biomarkers for osteosarcoma.
- GLO1's role in regulating oxidative stress and inflammation may be relevant to OS pathogenesis.
- Further research is warranted to validate these proteomic findings and explore therapeutic targets for OS.
